Financials data is unavailable for this security.
View more
Year on year Touyun Biotech Group Ltd 's revenues fell -37.10%from 315.83m to 198.64m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 35.78% reduction in net income from a loss of 198.07m to a larger loss of 268.94m.
Gross margin | 32.34% |
---|---|
Net profit margin | -139.37% |
Operating margin | -135.02% |
Return on assets | -35.67% |
---|---|
Return on equity | -335.55% |
Return on investment | -97.59% |
More ▼
Cash flow in HKDView more
In 2023, cash reserves at Touyun Biotech Group Ltd fell by 93.61m. However, the company earned 3.65m from its operations for a Cash Flow Margin of 1.84%. In addition the company used 70.95m on investing activities and also paid 27.68m in financing cash flows.
Cash flow per share | -0.0689 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.0166 |
---|---|
Tangible book value per share | -0.0166 |
More ▼
Balance sheet in HKDView more
Current ratio | 0.3392 |
---|---|
Quick ratio | 0.3063 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.07 |
More ▼